John Leonard

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. pmc Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma
    Biree Andemariam
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
    Biologics 1:113-20. 2007
  2. ncbi request reprint Biology and management of mantle cell lymphoma
    J P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Oncol 13:342-7. 2001
  3. ncbi request reprint New developments in immunotherapy for non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Curr Oncol Rep 7:364-71. 2005
  4. ncbi request reprint Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 23:5696-704. 2005
  5. ncbi request reprint Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
    John P Leonard
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 10:5327-34. 2004
  6. ncbi request reprint Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma
    John P Leonard
    Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, NY 10021, USA
    Int J Cancer 119:971-9. 2006
  7. doi request reprint Novel agents for follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2010:259-64. 2010
  8. doi request reprint Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York, USA
    Cancer 113:2714-23. 2008
  9. ncbi request reprint Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
    J Clin Oncol 21:3051-9. 2003
  10. ncbi request reprint Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma
    John P Leonard
    Oncology Services, New York Presbyterian Hospital, New York Weill Cornell Medical Center, Starr Pavilion, Room ST 340, 520 East 70th Street, New York, NY 10021, USA
    Cancer Invest 21:241-52. 2003

Research Grants

Detail Information

Publications86

  1. pmc Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma
    Biree Andemariam
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
    Biologics 1:113-20. 2007
    ..These data suggest that this agent has an important role in the treatment of patients with B cell lymphoma...
  2. ncbi request reprint Biology and management of mantle cell lymphoma
    J P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Oncol 13:342-7. 2001
    ..Overall, the prognosis for patients with mantle cell lymphoma remains poor, and novel strategies are needed...
  3. ncbi request reprint New developments in immunotherapy for non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Curr Oncol Rep 7:364-71. 2005
    ..Further studies of unlabeled and radiolabeled immunotherapies are ongoing in order to optimize their use for maximal clinical benefit...
  4. ncbi request reprint Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 23:5696-704. 2005
    ..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma...
  5. ncbi request reprint Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
    John P Leonard
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 10:5327-34. 2004
    ..We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma...
  6. ncbi request reprint Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma
    John P Leonard
    Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, NY 10021, USA
    Int J Cancer 119:971-9. 2006
    ..A number of combination trials are currently underway with a range of standard agents. Bortezomib has the potential to play a significant role throughout the NHL treatment algorithm in the future...
  7. doi request reprint Novel agents for follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2010:259-64. 2010
    ....
  8. doi request reprint Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York, USA
    Cancer 113:2714-23. 2008
    ..In this international, multicenter trial, the authors evaluated rituximab (anti-CD20) plus epratuzumab (anti-CD22) in patients with postchemotherapy relapsed/refractory, indolent non-Hodgkin lymphoma (NHL), including long-term efficacy...
  9. ncbi request reprint Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
    J Clin Oncol 21:3051-9. 2003
    ..This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL)...
  10. ncbi request reprint Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma
    John P Leonard
    Oncology Services, New York Presbyterian Hospital, New York Weill Cornell Medical Center, Starr Pavilion, Room ST 340, 520 East 70th Street, New York, NY 10021, USA
    Cancer Invest 21:241-52. 2003
    ..Further studies are needed, however, to determine if the differences in the pharmacology of 131I and 90Y are clinically relevant...
  11. ncbi request reprint Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
    J P Leonard
    Department of Medicine, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Oncogene 26:3704-13. 2007
    ..Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens...
  12. ncbi request reprint A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
    J P Leonard
    Division of Hematology Oncology, Weill Medical College of Cornell University and NewYork Presbyterian Hospital, New York, NY 10021, USA
    Ann Oncol 18:1216-23. 2007
    ..A phase I/II study was conducted to evaluate galiximab in combination with a standard course of rituximab. Safety, pharmacokinetics, and efficacy were evaluated...
  13. ncbi request reprint Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 23:5044-51. 2005
    ..To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL)...
  14. ncbi request reprint Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Clin Adv Hematol Oncol 6:437-45. 2008
    ..This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL...
  15. ncbi request reprint Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Jodi V Mones
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 48:342-8. 2007
    ..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses...
  16. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone
    Morton Coleman
    Specialized Center of Research for Multiple Myeloma, Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, NY, USA
    Semin Oncol 30:270-4. 2003
    ..BLT-D is effective in WM. Because of its toxicity, predominantly neurological, BLT-D may best serve as an induction regimen or to "rescue" patients with refractory disease or disease-related low counts...
  17. doi request reprint Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma
    Morton Coleman
    Division of Hematology Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
    Leuk Lymphoma 49:447-50. 2008
    ....
  18. ncbi request reprint FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
    Lale Kostakoglu
    Department of Radiology, Division of Nuclear Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 107:2678-87. 2006
    ....
  19. ncbi request reprint Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Alan D Dosik
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 106:616-22. 2006
    ..Hematologic reserve after radioimmunotherapy (RIT) is an important consideration when subsequent therapy is required...
  20. ncbi request reprint Epratuzumab: targeting B-cell malignancies through CD22
    Morton Coleman
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3991S-4S. 2003
    ..Efforts are underway to establish the utility of epratuzumab as a treatment for B-cell malignancies, through single agent and combination regimens, to define the optimal settings for its clinical application...
  21. ncbi request reprint Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
    John P Leonard
    Center for Lymphoma and Myeloma and Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Oncol 29:81-6. 2002
    ..Further efforts will explore optimal clinical settings for their use, as well as define treatment regimens either as single agents or in combination with chemotherapy or other biologics...
  22. ncbi request reprint CD22-directed monoclonal antibody therapy for lymphoma
    Abby B Siegel
    Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, NY, USA
    Semin Oncol 30:457-64. 2003
    ..Ongoing and future studies will further determine the role of epratuzumab among the array of antilymphoma therapies, both as a single agent and in combination with other agents...
  23. ncbi request reprint Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data
    Biree Andemariam
    Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY, USA
    Clin Lymphoma Myeloma 7:S20-3. 2006
    ..For now, these initial data suggest that patients with indolent lymphoma might derive significant benefit from these novel therapeutic strategies...
  24. ncbi request reprint Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma
    Lale Kostakoglu
    Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 94:879-88. 2002
    ....
  25. pmc Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
    Tomer Mark
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 14:795-8. 2008
    ..91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide...
  26. doi request reprint Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Hematol 45:126-32. 2008
    ..Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents...
  27. ncbi request reprint Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
    John P Leonard
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:6168-74. 2007
    ..This Phase I trial was designed to investigate the safety, tolerability, and preliminary antitumor activity of PF-3512676 in combination with rituximab...
  28. ncbi request reprint Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Leuk Lymphoma 48:2330-7. 2007
    ..Low-dose aspirin appears to reduce the incidence of thrombosis with these regimens. Routine use of aspirin as antithrombotic prophylaxis in MM patients receiving immunomodulatory drugs with corticosteroids is warranted...
  29. doi request reprint Individuals' willingness to talk to their doctors about clinical trial enrollment
    Katherine A McComas
    Department of Communication, Cornell University, 313 Kennedy Hall, Ithaca, NY 14853, USA
    J Health Commun 15:189-204. 2010
    ..Fairness of interactions and trust in doctors were less relevant to respondents who were less willing to talk to their doctors; however, these respondents also were more likely to express intentions to enroll in future clinical trials...
  30. doi request reprint Targeted treatment and new agents in diffuse large B-cell lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Hematol 45:S11-6. 2008
    ....
  31. ncbi request reprint PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
    Lale Kostakoglu
    Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    J Nucl Med 43:1018-27. 2002
    ....
  32. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007
    ..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting...
  33. ncbi request reprint Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital Cornell Medical Center, New York, NY 10021, USA
    Br J Haematol 138:640-3. 2007
    ..Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients...
  34. doi request reprint Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy
    Morton Coleman
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 112:2228-32. 2008
    ..Many patients with recurrent lymphoma are unable to tolerate intensive therapies, or have disease that is refractory. Metronomic chemotherapy offers a novel, potentially less toxic yet effective treatment strategy...
  35. pmc Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
    Tomer Mark
    Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Br J Haematol 143:654-60. 2008
    ..This is the first time this phenomenon has been seen with regularity in non-myeloablative therapy for MM. Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response...
  36. ncbi request reprint A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy
    Tsiporah Shore
    Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:868-75. 2006
    ....
  37. doi request reprint Mantle cell lymphoma: biological insights and treatment advances
    John P Leonard
    Center for Lymphoma and Myeloma, Clinical Research, Division of Hematology Oncology, New York Weill Cornell Medical Center, New York, NY, USA
    Clin Lymphoma Myeloma 9:267-77. 2009
    ....
  38. ncbi request reprint Antibodies in the treatment of lymphoma
    John P Leonard
    Oncology Services, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY, USA
    Clin Adv Hematol Oncol 2:210-1. 2004
  39. ncbi request reprint Epratuzumab in non-Hodgkin's lymphomas
    Richard R Furman
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th Street, New York, NY 10021, USA
    Curr Treat Options Oncol 5:283-8. 2004
    ..Because of important differences in the characteristics of CD22 compared to CD20, epratuzumab may become an important component of future therapies for NHL...
  40. ncbi request reprint The role of FDG-PET imaging in the management of lymphoma
    Lale Kostakoglu
    Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Adv Hematol Oncol 2:115-21. 2004
    ....
  41. doi request reprint Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
    Rebecca L Elstrom
    Center for Lymphoma and Myeloma, Weill Cornell Medical Center, New York, NY 10021, USA
    Clin Lymphoma Myeloma Leuk 10:192-6. 2010
    ..Chemotherapy responsiveness before transplantation is a major predictor of outcome. Patients not responding to second-line regimens may receive third-line therapy in the hopes of achieving response, but outcome data are limited...
  42. pmc Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
    Jia Ruan
    Division of Hematology Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, New York, USA
    Cancer 116:2655-64. 2010
    ....
  43. ncbi request reprint Milatuzumab: a promising new agent for the treatment of lymphoid malignancies
    Tomer Mark
    Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, NY 10021, USA
    Expert Opin Investig Drugs 18:99-104. 2009
    ..The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy...
  44. ncbi request reprint BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Blood 111:1101-9. 2008
    ..BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203...
  45. ncbi request reprint BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia
    Morton Coleman
    Specialized Center of Research for Multiple Myeloma, Weill Medical College of Cornell University and the Department of Medicine, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Leuk Lymphoma 43:1777-82. 2002
    ..Caution should be exercised when using thalidomide, alone or in combination, in patients with a preexisting tendency to thromboses, severe cardiopulmonary disease, or neurologic dysfunction...
  46. ncbi request reprint Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 13:5636s-5642s. 2007
    ..These promising therapeutics face a significant challenge in evaluation and integration in the post-rituximab world...
  47. ncbi request reprint Novel therapeutic targets in mantle cell lymphoma
    Peter Martin
    Weill Medical College of Cornell University and New York Presbyterian Hospital, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Building Room 340, 520 East 70th Street, New York, NY 10021, USA
    Expert Opin Ther Targets 11:929-40. 2007
    ..Here, the authors discuss the rationale for developing targeted therapies and discuss future challenges in combining some of these agents...
  48. pmc Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Cancer 116:106-14. 2010
    ..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
  49. doi request reprint New biologic agents and immunologic strategies
    Rebecca L Elstrom
    Division of Hematology Oncology, Weill Cornell Medical College, 520 East 70th Street, Starr 340, New York, NY 10021, USA
    Hematol Oncol Clin North Am 22:1037-49, x-xi. 2008
    ....
  50. ncbi request reprint Management of relapsed mantle cell lymphoma: still a treatment challenge
    Jia Ruan
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10065, USA
    Oncology (Williston Park) 23:683-90. 2009
    ..Involvement of a lymphoma center participating in clinical trials of novel MCL treatments is encouraged...
  51. ncbi request reprint The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
    Nichola Cooper
    Division of Hematology Oncology, Departments of Pediatrics and Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, USA
    Br J Haematol 125:232-9. 2004
    ..No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP...
  52. doi request reprint Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis
    Peter Martin
    Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Clin Lymphoma Myeloma 9:247-9. 2009
    ..An understanding of the pathophysiology of sepsis and immunologic activation that appear to have led to these long-term remissions might lead to novel therapeutic approaches for patients with HL...
  53. doi request reprint Improving outcomes for patients with Burkitt lymphoma and HIV
    Victoria S Blinder
    Divisions of Hematology Oncology and Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
    AIDS Patient Care STDS 22:175-87. 2008
    ..Further studies, including randomized clinical trials, are needed to better delineate the optimal treatment for patients with this devastating disease...
  54. pmc Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
    M R Baer
    University of Maryland, Department of Medicine, Baltimore, MD 21201, USA
    Leukemia 25:800-7. 2011
    ..001), increasing WBC (P=0.001) and age (P<0.001), poorer PS (P<0.001) and secondary AML (P=0.010). Outcomes and prognostic factors were similar to those in previous Cancer and Leukemia Group B studies...
  55. doi request reprint FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma
    Sarah C Rutherford
    Centre for Lymphoma and Myeloma, Division of Haematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 49:719-26. 2008
    ..Our findings support a potential role for preoperative FDG-PET in consideration of the need for splenectomy in these settings...
  56. ncbi request reprint Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion
    Myron S Czuczman
    Lymphoma Myeloma Service and Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute, Buffalo, New York, USA
    Clin Adv Hematol Oncol 8:A1-14; quiz A15. 2010
    ..Some of the drug classes examined here are proteasome inhibitors, inhibitors of the protein mammalian target of rapamycin (mTOR), the unique alkylating agent bendamustine, and immunomodulatory agents...
  57. ncbi request reprint Mantle cell lymphoma: current concept in biology and treatment
    Jia Ruan
    Center for Lymphoma and Myeloma and Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
    Cancer Treat Res 131:141-59. 2006
  58. ncbi request reprint IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
    Leuk Lymphoma 48:1259-60. 2007
  59. pmc Repeated courses of rituximab in chronic ITP: Three different regimens
    Aisha Hasan
    Division of Pediatric Hematology, Children s Blood Center, NY Presbyterian Hospital and Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Hematol 84:661-5. 2009
    ..Neither combining rituximab with CVP nor doubling the dose of rituximab increased the response rate...
  60. ncbi request reprint Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient
    Abby B Siegel
    Herbert Irving Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Leuk Lymphoma 48:225-6. 2007
  61. ncbi request reprint Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma
    Jia Ruan
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5622-31. 2006
    ..Here, we investigated whether stromal incorporation of CD68(+) hemangiogenic cells and alpha-smooth muscle actin(+) (alpha-SMA(+)) stromal cells correlates with neoangiogenesis and progression in human non-Hodgkin's lymphoma subtypes...
  62. doi request reprint Is there a role for "watch and wait" in patients with mantle cell lymphoma?
    Peter Martin
    Department of Medicine, Weill Cornell Medical College New York Presbyterian Hospital, New York, NY 10065, USA
    Semin Hematol 48:189-93. 2011
    ..Similarly, patients with less aggressive MCL may be an ideal group in which to evaluate novel treatment approaches...
  63. ncbi request reprint Hodgkin's lymphoma in HIV: unusual presentations and improving outcomes
    Abby B Siegel
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Adv Hematol Oncol 1:616-7. 2003
  64. ncbi request reprint Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
    Richard R Furman
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology and Weill Medical College of Cornell University and New York Presbyterian Hospital New York, NY, USA
    Cancer Treat Res 131:221-50. 2006
  65. doi request reprint Outcome of deferred initial therapy in mantle-cell lymphoma
    Peter Martin
    Starr Building Rm 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 27:1209-13. 2009
    ..Because data on observation, or "watch and wait," have not been previously reported, we analyzed the outcome of deferred initial therapy...
  66. ncbi request reprint Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Clin Lymphoma Myeloma 7:S192-8. 2007
    ..We discuss several combinations, their rationale, and the clinical evidence that justifies further evaluation...
  67. doi request reprint Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
    Jia Ruan
    Center for Lymphoma and Myeloma, Weill Cornell Medical College, 525 East 68th St, Starr 340, New York, NY 10065, USA
    J Clin Oncol 29:690-7. 2011
    ..We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)...
  68. doi request reprint Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib
    Zibo Song
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 16:587-99. 2010
    ..We aim to define the molecular mechanisms underlying the differential dasatinib sensitivity and to uncover more effective therapeutic targets in CLL...
  69. ncbi request reprint Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures
    Abby B Siegel
    Departments of Medical Oncology and Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Clin Lymphoma Myeloma 7:65-9. 2006
    ....
  70. doi request reprint Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    N Engl J Med 359:613-26. 2008
  71. ncbi request reprint Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 0001, USA
    J Clin Oncol 23:4390-8. 2005
    ..This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma...
  72. ncbi request reprint Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    John M Bennett
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 105:4576-82. 2005
    ..With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients)...
  73. ncbi request reprint The radioisotope contributes significantly to the activity of radioimmunotherapy
    Thomas A Davis
    Stanford University, Stanford, California, USA
    Clin Cancer Res 10:7792-8. 2004
    ....
  74. ncbi request reprint Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support
    John P Leonard
    Curr Hematol Rep 2:451-2. 2003
  75. ncbi request reprint Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Richard I Fisher
    University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 23:7565-73. 2005
    ....
  76. ncbi request reprint Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties
    Josette Carnahan
    Amgen, Inc, Thousand Oaks, California 91320, USA
    Clin Cancer Res 9:3982S-90S. 2003
    ..In this report, we present epratuzumab activities as they relate to binding, signaling, and internalization of the receptor CD22...
  77. ncbi request reprint Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  78. ncbi request reprint Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Richard I Fisher
    University of Rochester, James P Wilmot Cancer Center, Rochester, USA
    J Clin Oncol 24:4867-74. 2006
    ..Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  79. ncbi request reprint Combination treatment approaches and novel therapies for lymphoma
    John P Leonard
    Clin Adv Hematol Oncol 5:4-20; quiz 1 p following 20. 2007
  80. ncbi request reprint A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khuda D Khan
    American Health Network Oncology Hematology, Indianapolis, Indiana, USA
    Clin Cancer Res 12:7046-53. 2006
    ..Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted...
  81. pmc A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
    Nancy L Bartlett
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 111:1848-54. 2008
    ..These results demonstrate that weekly administration of SGN-30 is safe and has modest clinical activity in patients with CD30(+) tumors. This trial is registered at http://www.ClinicalTrials.gov as no. NCT00051597...
  82. ncbi request reprint TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammation
    Junqing Cui
    Wyeth Research, Cambridge, MA 02140, USA
    J Allergy Clin Immunol 115:309-15. 2005
    ..Although it is clear that T(H)2 cells and their cytokines play an important role in AHR, the roles of T(H)1 cells and neutrophils in AHR are controversial...
  83. ncbi request reprint Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
    Charles H Redfern
    Sharp HealthCare, San Diego, CA, USA
    J Clin Oncol 24:3107-12. 2006
    ..To evaluate idiotype (Id) vaccination as a single agent in previously treated patients with indolent non-Hodgkin's lymphoma...
  84. ncbi request reprint B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder
    David M Goldenberg
    Arthritis Rheum 54:2344; author reply 2344-5. 2006
  85. pmc A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degeneration
    Zubair Ahmed
    Department of Neuroinflammation, Institute of Neurology, University College London, United Kingdom
    Am J Pathol 161:1577-86. 2002
    ..Because caspase-3 is a downstream cell death signal it may be possible to reduce apoptosis by selectively blocking caspase-3 and therefore provide a therapeutic target for EAE and potentially, multiple sclerosis...
  86. ncbi request reprint New antibodies in the treatment of lymphoma
    John P Leonard
    Clin Adv Hematol Oncol 4:196-8. 2006

Research Grants5

  1. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2001
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..
  2. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2002
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..
  3. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2003
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..
  4. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2004
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..
  5. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2005
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..